Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid LeukemiaNicholas J. Short, Farhad Ravandi, Xuelin Huang et al.|JAMA Oncology|2020Cited by 380
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III TrialEnriqueta Felip, Nasser K. Altorki, Caicun Zhou et al.|Journal of Clinical Oncology|2025Cited by 44
Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysisNicholas J. Short, Farhad Ravandi, Chenqi Fu et al.|Leukemia|2022Cited by 42
IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC).Heather A. Wakelee, Enriqueta Felip, Nasser K. Altorki et al.|Journal of Clinical Oncology|2024Cited by 22